Kalydeco gains expanded use

Vertex Pharma announced FDA has approved Kalydeco (ivacaftor) for use in people with cystic fibrosis ages six and older exhibiting the R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

The nod in the US is the first approval to treat CF patients with the mutation and brings the total number of CFTR gene mutations in which the drug is approved for use to 10 Kalydeco, approved to treat CF in 2012.


Next Article in Legal/Regulatory